European Medicines Agency’s data protection notice regarding the experts database and the handling of competing interests of scientific committees’ members and experts

European Medicines Agency’s data protection notice regarding the experts database and the handling of competing interests of scientific committees’ members and experts

Draft qualification opinion for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology in liver biopsies to determine disease activity in NASH/MASH clinical trials

Draft qualification opinion for artificial intelligence-based measurement of non-alcoholic steatohepatitis histology in liver biopsies to determine disease activity in NASH/MASH clinical trials

Q&A Clinic on post-authorisation procedure management in IRIS - 11 Dec 2024, Online, from 11 December 2024, 11:00 (CET) to 11 December 2024, 12:00 (CET)

Q&A Clinic on post-authorisation procedure management in IRIS - 11 Dec 2024, Online, from 11 December 2024, 11:00 (CET) to 11 December 2024, 12:00 (CET)

Q&A Clinic on post-authorisation procedure management in IRIS (1), Online, from 11 December 2024, 11:00 (CET) to 11 December 2024, 12:00 (CET)

Q&A Clinic on post-authorisation procedure management in IRIS (1), Online, from 11 December 2024, 11:00 (CET) to 11 December 2024, 12:00 (CET)

Human medicines European public assessment report (EPAR): Alli (previously Orlistat GSK), orlistat, Date of authorisation: 22/07/2007, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Alli (previously Orlistat GSK), orlistat, Date of authorisation: 22/07/2007, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Vantavo (previously Alendronate sodium and colecalciferol, MSD), alendronic acid,colecalciferol, Date of authorisation: 16/10/2009, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Vantavo (previously Alendronate sodium and colecalciferol, MSD), alendronic acid,colecalciferol, Date of authorisation: 16/10/2009, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Adrovance, alendronic acid,colecalciferol, Date of authorisation: 04/01/2007, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Adrovance, alendronic acid,colecalciferol, Date of authorisation: 04/01/2007, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Esperoct, turoctocog alfa pegol, Date of authorisation: 20/06/2019, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Esperoct, turoctocog alfa pegol, Date of authorisation: 20/06/2019, Revision: 8, Status: Authorised

Clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Scientific guideline

Clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Scientific guideline

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness